DIZAL PHARMA
Dizal Pharmaceutical is a research-based biotechnology company dedicated to the discovery, development, and commercialization of first-in-class/best-in-class medicines.
DIZAL PHARMA
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2017-10-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.dizalpharma.com
Total Employee:
101+
Status:
Active
Contact:
+86-21-61097800
Email Addresses:
[email protected]
Total Funding:
100 M USD
Technology used in webpage:
SPF Domain Not Resolving Apache Microsoft Azure DNS Alibaba Zoom Video Conferencing Zoom HiChina DNS WebEx China Unicom
Similar Organizations
Asieris Pharmaceuticals
Asieris Pharmaceuticals is a Chinese biotech company.
Cinclus Pharma
Cinclus Pharma is a research based biotech company.
Kehui Seed
Kehui Seed is a research based biotech seed company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
Magpie Pharmaceuticals
Magpie Pharmaceuticals is a biotechnology company.
RetiPharma
RetiPharma is a Danish Biotech company
Ruidi Bio
Ruidi Biotechnology is a professional biotechnology service company.
Scipio Bioscience
A Paris-based biotechnology company .
Step Pharma
Step Pharma is a biotechnology company.
Suhua
Suhua is an innovative synthetic biotechnology skin care brand.
Veloce BioPharma
Veloce BioPharma is a biotechnology company.
Vitas Pharma
Vitas Pharma is a drug discovery company.
Current Employees Featured
Founder
Stock Details
Investors List
Wuxi NewForce Fund
Wuxi NewForce Fund investment in Venture Round - Dizal Pharma
Trinity Innovation Fund
Trinity Innovation Fund investment in Venture Round - Dizal Pharma
Lilly Asia Ventures
Lilly Asia Ventures investment in Venture Round - Dizal Pharma
Sequoia Capital China
Sequoia Capital China investment in Venture Round - Dizal Pharma
Official Site Inspections
http://www.dizalpharma.com Semrush global rank: 4.73 M Semrush visits lastest month: 1.99 K
- Host name: 101.132.107.158
- IP address: 101.132.107.158
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Dizal Pharma"
Dizal Pharma
Learning organization Compete to win. About Us. Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological …See details»
Dizal Pharma
迪哲医药（股票代码：688192）是一家全球创新型生物医药企业，专注于恶性肿瘤和免疫性疾病领域，致力于开发具备差异化竞争优势的全球创新药。基于行业领先的转化科学和新药分子设计与筛选技术平台，公司已建立了五个具备全球竞 …See details»
Dizal Pharma - Crunchbase Company Profile & Funding
Organization. Dizal Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email [email protected]; Phone …See details»
Dizal Pharmaceutical - LinkedIn
Dizal Pharmaceutical | 3,705 followers on LinkedIn. Dizal Pharmaceutical Co., Ltd (Ticker: 688192 ) is a commercial stage biopharmaceutical company. At Dizal we aspire to discover and develop ...See details»
Dizal Pharma - Products, Competitors, Financials, Employees ...
Headquarters Location. 199 Liangjing Rd, Zhangjiang Hi-Tech Park . Shanghai, Shanghai, 201203, China +86-21-61097800See details»
Dizal Pharma Company Profile 2024: Stock Performance
Information on stock, financials, earnings, subsidiaries, investors, and executives for Dizal Pharma. Use the PitchBook Platform to explore the full profile.See details»
Dizal Pharma
Report on Phase 1 Studies of DZD9008, an Oral, Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutation Has Been Selected for Oral Presentation at the …See details»
Dizal Impresses with Its Differentiated Hematological Oncology ...
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual …See details»
Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for ...
Feb 18, 2022 Dizal is conducting Phase II pivotal clinical trials in the U.S., China, Australia, South Korea and other countries and regions. About Dizal Pharmaceutical. Dizal …See details»
Breakthrough in Lung Cancer Treatment: Dizal to Unveil …
Apr 24, 2024 Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases, …See details»
CAREERS - Dizal Pharma
迪哲医药（股票代码：688192）是一家全球创新型生物医药企业，专注于恶性肿瘤和免疫性疾病领域，致力于开发具备差异化竞争优势的全球创新药。基于行业领先的转化科学和新药分子设计 …See details»
Dizal Pharma - Overview, News & Similar companies - ZoomInfo
Sep 5, 2023 LONDON & CHICAGO--(BUSINESS WIRE)-- #anova--Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its …See details»
Dizal Leads China's Biotech Innovation by Showcasing Strength of …
Jun 7, 2023 Two highly anticipated oral presentations captured attention: first pivotal study of sunvozertinib (WU-KONG6) and multinational pivotal study of golidocitinib...See details»
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet ...
Dec 13, 2023 Dizal today announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer (NSCLC) patients with …See details»
FDA Grants Breakthrough Therapy Designation for Dizal …
SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted …See details»
ASH: AZ spinout Dizal explores FDA path, US partner for PTCL med
Dec 11, 2023 Besides, 46 patients (52.3%) were still alive at the data cutoff, with a median overall survival of 19.4 months. In contrast, current standard treatments can only give this type …See details»
Dizal's Sunvozertinib Approved by China NMPA with Potential for …
Aug 23, 2023 /PRNewswire/ -- Dizal today announced that sunvozertinib has been approved by the National Medical Products Administration (NMPA) of China for the treatment of...See details»
NEWS DETAIL - Dizal Pharma
Feb 17, 2022 Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to DZD4205 …See details»
Dizal’s Sunvozertinib Approved by China NMPA with ... - BioSpace
Aug 23, 2023 Sunvozertinib cemented “best-in-class” position due to its superior efficacy and safety profile. Non-small cell lung cancer (NSCLC) is the most common type of cancer in …See details»
Dizal Submits New Drug Application to the U.S. FDA for
Nov 8, 2024 About sunvozertinib (DZD9008) Sunvozertinib is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type …See details»